Get the Stockscreener App
15.19
0.33%
-0.05
Pre-market:
15.67
0.48
+3.16%
Bausch Lomb Corp stock is traded at $15.19, with a volume of 297.87K.
It is down -0.33% in the last 24 hours and down -8.71% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$15.24
Open:
$15.27
24h Volume:
297.87K
Relative Volume:
0.48
Market Cap:
$5.35B
Revenue:
$4.68B
Net Income/Loss:
$-368.00M
P/E Ratio:
-14.47
EPS:
-1.05
Net Cash Flow:
$-58.00M
1W Performance:
-5.00%
1M Performance:
-8.71%
6M Performance:
-2.32%
1Y Performance:
-6.06%
1-Day Range:
$15.07
$15.32
1-Week Range:
$15.07
$16.15
52-Week Range:
$13.16
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
15.19 | 5.35B | 4.68B | -368.00M | -58.00M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
476.78 | 170.05B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
222.79 | 63.97B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
86.81 | 42.94B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
219.72 | 32.28B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.55 | 17.64B | 17.28B | 108.00M | 391.00M | 0.20 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update - GlobeNewswire Inc.
HC Wainwright Has Negative View of Bausch + Lomb Q1 Earnings - Defense World
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of “Hold” from Analysts - Defense World
Bank of America Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $17.00 - Defense World
Bausch + Lomb Corporation (NYSE:BLCO) Q4 2024 Earnings Call Transcript - Insider Monkey
Bausch & Lomb Begins to Reap Fruits of Innovation; Broad-Based Growth Fuels Our Long-Term Outlook - Morningstar
Bausch + Lomb Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance - BioSpace
Bausch + Lomb Corp. Announces FY25 Revenue Within View - Nasdaq
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results - TradingView
Bausch + Lomb Posts Q4 Revenue of US$1.28 Billion -February 19, 2025 at 06:59 am EST - Marketscreener.com
Short Interest in Bausch + Lomb Co. (NYSE:BLCO) Increases By 37.3% - MarketBeat
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Bausch + Lomb Sinks After Disclosing It Won’t Go Private Now - Bloomberg
Contact lens maker Bausch + Lomb rules out going private at this time - Reuters
Bausch + Lomb sinks after disclosing it won’t go private now - The Malaysian Reserve
Contact lens maker Bausch + Lomb rules out take-private deal - Yahoo Canada Finance
Bausch + Lomb Provides Update on Potential Sale - Business Wire
Brokerages Set Bausch + Lomb Co. (NYSE:BLCO) Target Price at $20.25 - MarketBeat
Stifel Nicolaus Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price - Defense World
Bausch Health Q4 Results to Focus on 2025 Outlook, Potential Full Separation of Bausch + Lomb, RBC Says - Marketscreener.com
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Bausch Lomb Corporation (BLCO-T) QuotePress Release - The Globe and Mail
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19 - Business Wire
This Bausch + Lomb Insider Increased Their Holding In The Last Year - Yahoo Finance
Ellsworth Advisors LLC Invests $665,000 in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Wells Fargo & Company Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $24.00 - Defense World
Bausch + Lomb bolsters pipeline with acquisition of Whitecap Biosciences - ROI-NJ.com
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences - BioSpace
Bausch + Lomb Launches enVista Aspire IOLs in Europe - TipRanks
Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union - Business Wire
B%2BL+affiliate+acquires+California-based+pharmaceutical+company+%C2%A0 - Rochester Business Journal
Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20? - Yahoo Finance
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine - Yahoo Finance
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy - Yahoo Finance
Implantable Drug Delivery Devices Business Research Report 2023-2024 & 2030 - GlobeNewswire Inc.
S&P 500 Futures Rise in Premarket Trading; Aurora Innovation, Bausch + Lomb Lead - Barron's
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge - Business Wire
Bausch + Lomb Co. (NYSE:BLCO) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Bausch + Lomb Co. (NYSE:BLCO) Shares Acquired by State Street Corp - Defense World
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Warburg Pincus to buy Bausch & Lomb for $3.67 bln - Reuters
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer - Yahoo Finance
Bausch + Lomb down after report that Blackstone could back away from takeover bid - MSN
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Y Intercept Hong Kong Ltd Makes New Investment in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.47%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):